Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q3 2025 · 10-Q
Revenue$1.08M$1.08M+774.8% vs Q3 2024 Net Income$200.64M$200.64MN/M vs Q3 2024 EPS Diluted$49.61$49.61N/M vs Q3 2024 Operating Income-$5,411,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,856,000N/M Margins · derivedOperating margin-502.9%+38271.1 pt vs Q3 2024
Net margin18646.5%+32535.9 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 10, 2025 · 41 d after period end